Pharmacy chain Walgreens Boots Alliance and other defendants on April 26 said they were not to blame for the opioid crisis in San Francisco, and that they acted responsibly when providing legal medications to patients in pain.
ReutersWalgreens Boots Alliance and Teva Pharmaceutical Industries Ltd. ignored the health risks when they created new markets for opioids, a lawyer for the city of San Francisco told a judge on April 25 during opening statements of the first trial to target manufacturers, distributors and pharmacies over the addictive pain medicines.
ReutersJohnson & Johnson agreed to pay $99 million to settle claims by West Virginia that it helped fuel an opioid addiction crisis in the state, removing the company from an ongoing trial that began earlier in April.
AbbVie company Allergan Aesthetics announced the celebration of a milestone moment for BOTOX® Cosmetic (onabotulinumtoxinA). April 15, 2022, marks 20 years since the U.S. Food and Drug Administration first approved the product to temporarily improve the look of moderate to severe glabellar lines, located between your eyebrows.
Reuters HealthWest Virginia’s attorney general on April 4 urged a judge to hold Johnson & Johnson, Teva Pharmaceutical Industries Ltd., and AbbVie Inc.’s Allergen liable for causing a “tsunami” of opioid addiction in the state.
Florida reached more than $878 million in settlements with CVS Health Corp. and three drug companies to resolve claims and avert a trial in April over their roles in fueling an opioid epidemic in the third most populous U.S. state.
Teva Pharmaceutical Industries and AbbVie will pay the state of Rhode Island a combined $28.5 million to settle opioid-related claims against the companies.
International eye-care products manufacturer Allergan announced positive outcomes from the AbbVie company’s Phase 3 study of a new treatment for presbyopia, as the ophthalmic solution AGN-190584 met primary and key secondary endpoints.
As we continue to sift through the barrage of information regarding survival rates, resurgence, vaccines, and secondary illnesses, COVID-19 and its economic impact continues to be a primary global burden. In the midst of those serious concerns, the health and life sciences (HLS) industry continues its accelerated journey of perpetual assessment and evolution. As the industry emerges from the pandemic effect, leaders are realizing that COVID-19 has provided crucial learnings to their organizations that will benefit the entire industry, according to Astound Commerce’s Tina Wilson.
